VXRT Vaxart Inc.

0.53
+0.15  (+38%)
Previous Close 0.38
Open 0.4
Price To Book 1.32
Market Cap 25,293,134
Shares 47,722,895
Volume 5,295,104
Short Ratio
Av. Daily Volume 428,491
Stock charts supplied by TradingView

NewsSee all news

  1. Vaxart Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    - $9 million Underwritten Public Offering Closed - - Oral Bivalent Norovirus Vaccine Meets Primary and Secondary Endpoints in Phase 1b Study - SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Vaxart,

  2. Vaxart Hosting Key Opinion Leader Meeting on the Health Economics of Norovirus Disease

    SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by

  3. Vaxart to Present Clinical Data From its Norovirus Phase 1b Study at Three Global Healthcare Conferences in October 2019

    SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by

  4. Vaxart Announces Pricing of $8 Million Underwritten Public Offering

    SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary

  5. Vaxart's Tableted Oral Bivalent Norovirus Vaccine Meets Primary and Secondary Endpoints in Phase 1b Study

    Both norovirus vaccines induced substantial immune responses with no indicationof immunological interference when administered concurrently Phase 2-ready oral norovirus vaccine targets potential $3B+ market opportunity

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial did not meet primary endpoint.
BTA074 5% topical gel (teslexivir)
Condyloma
Phase 2 trial to be initiated 2020.
Norovirus vaccine
Norovirus vaccine

Latest News

  1. Vaxart Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    - $9 million Underwritten Public Offering Closed - - Oral Bivalent Norovirus Vaccine Meets Primary and Secondary Endpoints in Phase 1b Study - SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Vaxart,

  2. Vaxart Hosting Key Opinion Leader Meeting on the Health Economics of Norovirus Disease

    SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by

  3. Vaxart to Present Clinical Data From its Norovirus Phase 1b Study at Three Global Healthcare Conferences in October 2019

    SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by

  4. Vaxart Announces Pricing of $8 Million Underwritten Public Offering

    SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary

  5. Vaxart's Tableted Oral Bivalent Norovirus Vaccine Meets Primary and Secondary Endpoints in Phase 1b Study

    Both norovirus vaccines induced substantial immune responses with no indicationof immunological interference when administered concurrently Phase 2-ready oral norovirus vaccine targets potential $3B+ market opportunity

  6. Vaxart to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Wouter Latour, M.D., president and chief executive